When a useful therapy isn't being used.
snip
...
Researchers say that the drug’s rollout has been hampered by worries about ‘rebound’ (the mysterious return of symptoms or detectable virus days after a person starts to feel better) and side effects — as well as by declining concern about the risk of COVID-19. Inadequate funding for distribution, the drug’s high price tag and the need for it be taken soon after infection have also slowed its uptake. As a result, physicians have prescribed the drug in only about 0.5% of new COVID-19 cases in the United Kingdom, and in about 13% in the United States, according to a report by the health-analytics firm Airfinity, based in London, UK. Even doctors have reported serious difficulties in helping their family members to obtain Paxlovid1.
...
a tip of the hat to Sukie
Comments